Phase 1
N=6
Augmenting Flortaucipir Dosimetry Estimates
Alzheimer's Disease
Bottom Line
View on ClinicalTrials.gov: NCT02336360 ↗Enrolled (actual)
6
Serious AEs
—
Results posted
Aug 2020
Primary outcome: Primary: Urine Analysis - Total Integrated Radioactivity Excreted in Urine — 0.1413 megabecquerel-hours per megabecquerel
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 1
- Interventions
- Flortaucipir F18 (Drug)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- Avid Radiopharmaceuticals
- Primary completion
- Jun 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Urine Analysis - Total Integrated Radioactivity Excreted in Urine |
0.1413 | — |
Summary
This study will obtain data from urine in subjects administered flortaucipir in an Avid-sponsored study to augment the calculation of radiation dosimetry estimates.
Eligibility Criteria
Inclusion Criteria
- Subjects who passed screening in an Avid-sponsored study in which flortaucipir will be administered
Exclusion Criteria
- Subjects who have withdrawn informed consent
- Investigator or sponsor believes it is in the best interest of the subject to be removed from the trials
Data sourced from ClinicalTrials.gov (NCT02336360). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.